Merck

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company employs a precision medicine approach to create targeted oncology solutions. Its lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing mirdametinib, an oral small molecule MEK inhibitor, which is undergoing Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas. The company is also exploring various combination therapies involving nirogacestat and mirdametinib for multiple myeloma and solid tumors. SpringWorks has established collaborations with notable organizations to enhance its research and development efforts, aiming to unlock new treatment options for underserved patient populations.

Ambrosia Biosciences is a drug discovery company focused on developing small molecule-based therapies aimed at treating obesity and other metabolic disorders. The company provides innovative solutions that utilize non-invasive methods for weight management and improving metabolic health. By prioritizing patient comfort and minimizing side effects compared to traditional medications, Ambrosia Biosciences seeks to enhance the management of these conditions effectively.

UnitySC is a globally recognized leader in inspection and metrology, specializing in advanced technologies such as automated optical inspection and 3D imaging. By offering customized solutions tailored to specific industrial requirements, UnitySC empowers customers to enhance yields and accelerate time to market. Through innovative techniques like high depth of focus line scanning and spectrometry, UnitySC enables a new era in process control, facilitating efficient and precise manufacturing operations.

Proteologix is a precision immunology company powered by proprietary multi-specific antibody technologies. The company is dedicated to the discovery and development of safe and convenient therapeutics that target multiple disease-driving pathways to potentially deliver high-bar efficacy for patients with immune-mediated diseases.

Eurocine Vaccines specializes in developing nasal flu vaccines tailored for children and the elderly. The company oversees every aspect of vaccine development, from preclinical and clinical trials to manufacturing scalability, business development, and securing funding.

Aktis Oncology is a biotechnology company focused on the discovery and development of a new class of targeted radiopharmaceuticals aimed at treating various solid tumor cancers. The company has developed proprietary platforms to create tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered for high tumor penetration and prolonged residence time, allowing for effective tumor elimination while reducing the side effects typically associated with cancer treatments. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing treatment precision and efficacy.

Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.

Chord Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2014. It focuses on developing innovative drug therapies for rare and severely disabling diseases, specifically targeting conditions such as neuromyelitis optica spectrum disorders and myasthenia gravis. The company is advancing its lead drug candidate, CRD1, which has received orphan drug designation to address these critical health challenges. Chord Therapeutics is dedicated to repurposing small molecule drugs to provide effective treatments that can significantly improve the quality of life for patients suffering from these rare neurological disorders.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Chekkit is a technology company that provides an anti-counterfeiting solution powered by a DAG blockchain, specifically designed for the food and drug supply chain. The platform enables producers to protect their brands by offering real-time product authentication and tracking of supply chain activities. Additionally, Chekkit facilitates consumer engagement and collects valuable insights from the last mile of the supply chain. By equipping producers of fast-moving consumer goods (FMCG) and pharmaceuticals with tools to combat counterfeiting, Chekkit helps them regain market share and enhance sales while ensuring the integrity of their products.

Formo is Europe's pioneering cellular agriculture company specializing in the development of animal-free dairy products. By utilizing precision fermentation, Formo harvests real, nature-identical milk proteins that allow for the creation of clean and sustainable dairy alternatives. The company aims to provide vegan food options that retain the taste and nutritional benefits of traditional dairy while promoting a more sustainable and equitable food system. Through innovative biotechnology, Formo transforms nutrients into high-quality milk proteins, catering to the growing demand for healthier and environmentally friendly dairy products.

Chekkit is a technology company that provides an anti-counterfeiting solution powered by a DAG blockchain, specifically designed for the food and drug supply chain. The platform enables producers to protect their brands by offering real-time product authentication and tracking of supply chain activities. Additionally, Chekkit facilitates consumer engagement and collects valuable insights from the last mile of the supply chain. By equipping producers of fast-moving consumer goods (FMCG) and pharmaceuticals with tools to combat counterfeiting, Chekkit helps them regain market share and enhance sales while ensuring the integrity of their products.

Akili Labs is a biomedical startup based in South Africa that specializes in medical diagnostic technology. Founded in 2017 by Charles Faul and Lucas Lotter, with Dr. Farhan Pervaiz joining as a co-founder in 2018, the company aims to enhance healthcare through the development of molecular diagnostic tools. Akili Labs focuses on creating rapid diagnostic systems capable of testing for various viruses, bacterial and fungal infections, as well as performing specific gene screenings. By providing location-appropriate diagnostic solutions, the company enables healthcare professionals to reduce diagnostic costs and improve access to healthcare across Africa. With a commitment to innovation and collaboration, Akili Labs actively partners with organizations worldwide to design and implement healthcare and diagnostic-related products, addressing the critical need for quick and accurate diagnoses in the healthcare system.

Bluewave offer end to end product and process design for technology driven insurance solutions ensuring that products are accessible

Epilert is a company that specializes in wearable technology aimed at supporting individuals with neurological conditions, particularly epilepsy. Founded in 2017 and based in Tunis, Tunisia, Epilert has developed an artificial intelligence-based smart bracelet that monitors the wearer’s physiological data in real-time. Utilizing advanced sensors and machine learning algorithms, the device detects seizures and provides timely alerts to caregivers through a connected mobile application. In addition to seizure detection, the bracelet also tracks physical activity and sleep patterns, enhancing the overall well-being of users and enabling better access to healthcare when needed.

Intermolecular, Inc. is a technology company based in San Jose, California, that specializes in the development of advanced materials through its high productivity combinatorial (HPC) technology platform. Founded in 2004, Intermolecular offers an integrated Tempus HPC Platform, which includes processing tools, automated characterization methods, and informatics analysis software aimed at enhancing materials discovery and process development for industries such as semiconductors, consumer electronics, automotive, and aerospace. The company also provides various workflow systems for applications like self-assembly processing and surface preparation, using established chemical vapor deposition, physical vapor deposition, and atomic layer deposition methods. Intermolecular serves a diverse clientele, including semiconductor manufacturers, materials suppliers, and equipment producers, with a specific focus on the semiconductor, biotechnology, and energy sectors, primarily in the Asia-Pacific region. It operates as a subsidiary of MERCK Kommanditgesellschaft auf Aktien.

Versum Materials, Inc. is a global provider of specialty materials specifically designed for the semiconductor and display industries, with operations in the United States, Taiwan, South Korea, China, Europe, and other regions in Asia. The company operates through two main segments: Materials and Delivery Systems and Services (DS&S). The Materials segment offers a range of high-purity chemicals and gases utilized in semiconductor manufacturing, including materials for deposition, metallization, and cleaning processes, as well as chemical slurries and organometallics. The DS&S segment focuses on the development and manufacturing of systems for managing the delivery of gases and chemicals, alongside providing project management, maintenance services, and on-site support to optimize the inventory and operations of these materials. Founded in 2015 and headquartered in Tempe, Arizona, Versum Materials emphasizes collaboration and innovation to address the evolving needs of its customers in the high-tech materials sector.

Mosaic is a technology company that provides children's precise development and professional rehabilitation services.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

RxAll, Inc. is a technology company that specializes in developing an artificial intelligence-driven platform for the authentication and distribution of pharmaceuticals, primarily in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) platform that incorporates a molecular sensor device and a cloud database of spectral signatures. This innovative approach allows for non-destructive authentication of medications, including prescription and over-the-counter drugs, before they are dispensed. RxAll aims to combat the issue of counterfeit drugs by providing real-time information to pharmaceutical manufacturers about the authenticity of their products. Additionally, the platform facilitates access to authenticated medicines for patients and pharmacies, while also offering tele-pharmacy primary care services.

Grzybowski Scientific Inventions (GSI) is a start-up company with exclusive licensing, development, marketing and sales rights to the revolutionary chemistry decision-making and synthetic planning software product Chematica. Since its establishment in December 2013, GSI has successfully engaged a clientele composed of a wide range of industries as well as academic and government institutions from all over the world.

Clustermarket LTD. is an innovative online platform based in London that facilitates resource sharing for the life sciences sector. Established in 2015, the company provides a comprehensive solution for scientists to list, discover, and book essential equipment, software, lab space, and expertise within their institutions or clusters. Clustermarket serves a diverse clientele, including small startups, spin-outs, and established universities, aiming to streamline the management of research and democratize access to costly laboratory resources. Its award-winning lab management software and marketplace enable life scientists and biotechnologists to efficiently connect with service providers, allowing them to reserve laboratory tools and services at competitive rates. By bringing laboratory management into the digital age, Clustermarket enhances collaboration and accelerates the path from innovative ideas to market-ready solutions.

Fresh Strips is a smart packaging company focused on delivering cost-effective solutions that enhance the safety of heat-sensitive food products. The company has developed an innovative product consisting of a plastic sticker that can be affixed to food packaging. This sticker changes color in response to heat exposure, providing consumers with a clear indication of whether the food is safe for consumption. By informing consumers about the safety and quality of their food, Fresh Strips aims to improve food safety standards and reduce the risk of foodborne illnesses.

Ormet Circuits, Inc. is a manufacturer specializing in the design and production of electrically conductive sintering pastes and inks for the microelectronics and printed circuit board industries. Established in 2001 and based in San Diego, California, the company offers a range of lead-free copper-based products that cater to applications in semiconductor packaging, die attach, and electromagnetic shielding, among others. Its product lineup includes sintering pastes designed for filling micro via structures, forming Z-axis interconnections, and creating circuit traces. Ormet Circuits also provides alternatives to traditional solder paste and thermally conductive die attach materials. The company operates globally through a network of distribution and representative organizations and is a subsidiary of Merck KGaA.

Qlight Nanotech specializes in the development of semiconductor nanocrystals that possess distinctive optical and electrical properties. These nanocrystals facilitate the conversion of light from ultraviolet and blue wavelengths to any other wavelength within the visible spectrum. The emitted light's color, determined by the nanoparticles' size, achieves exceptional accuracy in both color and wavelength, complemented by high quantum efficiency. This technology enhances energy efficiency and reduces costs in solid-state lighting systems, such as LEDs, as well as in flat panel displays and various optical applications. By minimizing energy loss during the frequency conversion process, Qlight's innovations significantly improve the performance of liquid crystal display screens and LED lighting solutions.

Sigma-Aldrich is a prominent life science and high technology company that specializes in providing a wide range of organic chemical products, kits, and services. These offerings are integral to scientific research, biotechnology, pharmaceutical development, and disease diagnosis, playing a crucial role in advancing scientific breakthroughs. The company's products are also essential components in various manufacturing processes within the pharmaceutical and diagnostic sectors, as well as other high-tech industries. Operating in 40 countries, Sigma-Aldrich employs around 7,600 individuals dedicated to delivering high-quality solutions and excellent service to clients worldwide.

AZ Electronic Materials S.A. is a producer and supplier of specialty chemical materials for the electronics market, catering primarily to manufacturers of integrated circuits and flat panel displays. The company operates through various segments, including IC Materials, Optronics, and Printing and Other. Its advanced technology products are essential for a range of applications, including integrated circuits, devices, light-emitting diodes, and photolithographic printing. With a focus on innovation, AZ Electronic Materials provides critical materials that support the development and manufacturing processes within the electronics industry.

CellASIC is a biotechnology company that develops microfluidic platform for live cell analysis experiments by facilitating long-term perfusion cell culture. The company engineers platforms that utilize cutting edge microfluidics technology to provide superior live cell analysis with dynamic flow control. The company is founded on 2005 and is headquartered in Hayward, California.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Seven Seas Ltd. provides vitamins, minerals, and supplements worldwide. It offers liver oils, health oils, jointcare products, multivitamins, skin nutrition products, pregnancy products, immune support products, cold and flu relief products, and pulse/cardiom products. The company’s products are used in various applications, such as everyday health, digestive health, exercise and sport, immunity, cold and flu relief, tiredness reduction, energy, brain health, hectic living, heart health, joint health, women's health, pregnancy nutrition, new mums, skin health, hair and nail health, menopause, children's health, teen health, 50+ health, and men's health.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative drugs targeting oncology and rare diseases. Based in Exton, Pennsylvania, the company focuses on utilizing DNA- and RNA-based drug candidates to treat a variety of conditions, including cancer, autoimmune disorders, and infectious diseases. Its lead product, Tilsotolimod, is a TLR9 agonist designed to enhance immune responses against solid tumors and is currently in clinical trials for several types of cancer. Idera also develops a range of other TLR-based compounds, including agonists and antagonists, to modulate immune responses. The company has established various collaborations with major pharmaceutical firms to advance its research and commercialization efforts, enhancing its capabilities in the biopharmaceutical landscape. Founded in 1989, Idera Pharmaceuticals continues to drive innovation in therapeutic solutions for unmet medical needs.

Suzhou Taizhu Technology Development Co., Ltd. is manufactures and supplies effect pigments for printing, plastics, coating, and cosmetics industries.

LITEC-LLL is develops, produces, and markets custom phosphors. It offers LED phosphors for lamps, and blue and UV-LEDs, as well as phosphor mixtures. The company also produces ortho-silicate lighting materials, as well as provides lighting engineering services.

BioVascular is a clinical stage biotechnology company focused on developing innovative products to address platelet-mediated cardiovascular diseases. Its lead product, saratin, is a recombinant polypeptide produced in yeast, which was originally discovered and licensed from Merck KGaA. The company is currently conducting human clinical trials for saratin, targeting applications in hemodialysis access grafts and peripheral artery grafts, with the aim of reducing intimal hyperplasia, a condition that can lead to graft failure. BioVascular's mission is to create novel therapeutics that address significant unmet medical needs in the treatment and prevention of vascular diseases, thereby improving patient outcomes in cardiovascular health.

Merck Serono S.A. discovers, develops, manufactures, and commercializes prescription medicines focusing on various therapeutic areas that include oncology, immuno-oncology, immunology, multiple sclerosis, fertility, endocrinology, biosimilars, and neglected diseases. It develop treatments to help manage neurodegenerative diseases, such as multiple sclerosis; colorectal cancer; drugs to treat head and neck cancer; fertility drugs for every stage of the reproductive cycle.

Survac ApS focuses on the development of peptide based therapeutic cancer vaccines. It intends to offer the vaccine candidates for licensing and collaboration agreements.

ProVantage Healthcare is a leading health benefit management company providing pharmacy benefit management and health information technology products and services to their customers. Their goal is to be the leading third-party supplier of products and services designed to optimize the quality and minimize the cost of healthcare services. As of January 1999, they provided services to over 3,500 customers, including pharmacy benefit management services covering approximately 4.5 million individuals and vision benefit management services covering approximately 500,000 individuals. In addition, their licensed products, which are designed to improve the quality of healthcare, are being used by their clients in programs covering over 13 million people. They have experienced significant growth since fiscal 1995, increasing revenues from $81.2 million to $643.3 million in fiscal 1998, representing a compound annual growth rate of approximately 99%. Approximately 75% of their growth in the number of people who use their pharmacy benefit management services during this period has been generated internally rather than through acquisitions.

Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.